Evidence map›Paper›PMID 35326807›Full record

ReviewAntibiotics (Basel, Switzerland)2022

Isavuconazole in the Treatment of

Beatrijs Mertens, Ruth Van Daele, Melissa Depypere, Katrien Lagrou, Yves Debaveye, Joost Wauters, Stefaan Nijs, Willem-Jan Metsemakers, Isabel Spriet

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Fracture-related infection.Nature reviews. Disease primers · 2022
    Review
  3. Therapeutic advances in infectious disease
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Beatrijs MertensDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, B-3000 Leuven, Belgium.ORCID 0000-0002-1501-3045
Ruth Van DaeleDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, B-3000 Leuven, Belgium.ORCID 0000-0002-8353-2103
Melissa DepypereClinical Department of Laboratory Medicine, University Hospitals Leuven, B-3000 Leuven, Belgium.
Katrien LagrouClinical Department of Laboratory Medicine, University Hospitals Leuven, B-3000 Leuven, Belgium.ORCID 0000-0001-8668-1350
Yves DebaveyeDepartment of Cellular and Molecular Medicine, KU Leuven, B-3000 Leuven, Belgium.
Joost WautersClinical Department of Laboratory Medicine, University Hospitals Leuven, B-3000 Leuven, Belgium.
Stefaan NijsDepartment of Development and Regeneration, KU Leuven, B-3000 Leuven, Belgium.
Willem-Jan MetsemakersDepartment of Development and Regeneration, KU Leuven, B-3000 Leuven, Belgium.ORCID 0000-0002-4114-9093
Isabel SprietDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, B-3000 Leuven, Belgium.
KU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antifungal treatmentAspergillusbone penetrationfracture-related infectioninvasive aspergillosisisavuconazoleosteomyelitis

Identifiers

PMID35326807
PMCPMC8944859
OpenAlexW4221082485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.